Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
Dez. 2006 · John Wiley & Sons
E-Book
391
Seiten
reportBewertungen und Rezensionen werden nicht geprüft Weitere Informationen
Über dieses E-Book
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Autoren-Profil
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Dieses E-Book bewerten
Deine Meinung ist gefragt!
Informationen zum Lesen
Smartphones und Tablets
Nachdem du die Google Play Bücher App für Android und iPad/iPhone installiert hast, wird diese automatisch mit deinem Konto synchronisiert, sodass du auch unterwegs online und offline lesen kannst.
Laptops und Computer
Im Webbrowser auf deinem Computer kannst du dir Hörbucher anhören, die du bei Google Play gekauft hast.
E-Reader und andere Geräte
Wenn du Bücher auf E-Ink-Geräten lesen möchtest, beispielsweise auf einem Kobo eReader, lade eine Datei herunter und übertrage sie auf dein Gerät. Eine ausführliche Anleitung zum Übertragen der Dateien auf unterstützte E-Reader findest du in der Hilfe.
